Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A clinical trial to test a new treatment for Dupuytren’s disease has commenced at the Kennedy Institute and Botnar Research Centre. Affecting 4% of the UK population, this disease causes fingers to curl into the palm and can be extremely disabling.

A clinical trial to test a new treatment for Dupuytren's disease has commenced at the Kennedy Institute and Botnar Research Centre. Affecting 4% of the UK population, this disease causes fingers to curl into the palm and can be extremely disabling.

The team led by Professor Nanchahal has already unraveled the molecular mechanisms that initiate and maintain the disease process. The clinical trial will look at the next step - to test a new treatment with anti-TNF, a drug currently approved for use in patients with rheumatoid arthritis. If effective, this will represent the first targeted therapy involving a simple injection for patients with early Dupuytren's disease that will preserve hand function and avoid the need for subsequent more invasive treatments such as surgery.

Professor Nanchahal says "this is another exciting example of bench to bedside translation of findings based on tissues from patients".

Currently, there is no approved treatment for early disease. Once patients have established deformities, the diseased tissue is removed surgically or cut using less invasive techniques such as a needle or an enzyme. However, recovery following surgery usually takes several months and recurrence rates with the non-surgical techniques are high.

This research is funded by the Health Innovation Challenge Fund (Wellcome Trust + Department of Health).

Similar stories

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.

Defining the role of resident memory B cells in the fight against influenza

Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.